This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.
PFENegative Net Change NVAXNo Net Change OCGNPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
After Golden Cross, Entergy (ETR)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ETRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
4 Biotechs That Could Be Potential Takeover Targets in 2022
by Ekta Bagri
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
ALNYNegative Net Change BIIBNegative Net Change BMRNNegative Net Change ADAPPositive Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing medical pharmaceuticals
Dow, S&P Set Fresh All-Time Closing Highs
by Mark Vickery
Value plays look to have dried up during the past few sessions that account for the front end of the Santa Claus Rally.
BIIBNegative Net Change NKEPositive Net Change
biotechnology biotechs finance
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNNegative Net Change GILDNegative Net Change CDMOPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal
by Zacks Equity Research
Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.
GSKNegative Net Change PSTIPositive Net Change SRPTNegative Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More
by Zacks Equity Research
Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.
BIIBNegative Net Change GILDNegative Net Change NVAXNo Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs pharmaceuticals
Black Knight (BKI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BKINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 ADRs That More Than Doubled S&P 500 Returns in 2021
by Nalak Das
We have narrowed our search to five ADR stocks that have rallied more than double the S&P 500 Index in 2021. These are: ASML, SSL, EQNR, WIT and ERJ.
ERJNegative Net Change WITPositive Net Change ASMLNegative Net Change SSLPositive Net Change EQNRPositive Net Change
alt-energy biotechnology oil-energy semiconductor tech-stocks
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
BIIBNegative Net Change MRNANegative Net Change RGENPositive Net Change SRPTNegative Net Change BGNEPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals vaccines
Stock Market News for Dec 27, 2021
by Zacks Equity Research
U.S. stocks closed higher for the third consecutive day on Thursday, with the S&P 500 hitting a record high ahead of a long Christmas holiday weekend as investors shed fears and felt more optimistic that the Omicron variant of the coronavirus won¿¿¿t affect global economy growth.
MSFTPositive Net Change PFENegative Net Change MRKNegative Net Change NVDAPositive Net Change
biotechnology biotechs pharmaceuticals semiconductor tech-stocks
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.
DVAXNegative Net Change MRNANegative Net Change PRTANegative Net Change NTLANegative Net Change BNTXNegative Net Change
biotechnology biotechs crispr gene-editing medical vaccines
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health.
ATAINegative Net Change CMPSNegative Net Change PSILNegative Net Change
biotechnology medical
Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ARNAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Corning (GLW) Accelerates Vial Manufacturing at Durham Facility
by Zacks Equity Research
Corning (GLW) launches a new variety of vials in addition to its existing capacity to boost production rates at its Durham facility.
HLITNegative Net Change GLWPositive Net Change KVHINegative Net Change SEACPositive Net Change
biotechnology pharmaceuticals tech-stocks
Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.
CDMOPositive Net Change
biotechnology medical
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022
EWNegative Net Change MLABNegative Net Change SRTSNegative Net Change
biotechnology earnings genetics investing medical medical-devices pharmaceuticals smart-health
Company News for Dec 14, 2021
by Zacks Equity Research
Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.
PFENegative Net Change ARNAPositive Net Change LLYPositive Net Change TPXNegative Net Change NAVINegative Net Change FHTXNegative Net Change
biotechnology finance medical pharmaceuticals retail
Stock Market News for Dec 9, 2021
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.
GSKNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology pharmaceuticals
5 Top-Ranked ETFs to Buy At Bargain Prices
by Sweta Killa
With the easing of Omicron fears, Wall Street jumped to start a new week after a broad market sell-off in the past couple of weeks.
SPYPositive Net Change XRTNegative Net Change XBINegative Net Change VFHNegative Net Change SPVUPositive Net Change XMVMNegative Net Change
biotechnology etfs finance retail
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change NVAXNo Net Change BNTXNegative Net Change
biotechnology vaccines
Should You Buy HP (HPQ) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
HPQNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Fluor (FLR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FLRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Wall Street Tumbles on Resurgence of Coronavirus
by Zacks Equity Research
Wall Street Tumbles on Resurgence of Coronavirus.
PFENegative Net Change UANegative Net Change MRNANegative Net Change TRIPNo Net Change NCLHPositive Net Change ZMNegative Net Change PTONNegative Net Change BNTXNegative Net Change
airlines biotechnology consumer-discretionary pharmaceuticals tech-stocks travel-leisure